Kate Haviland - 12 Sep 2024 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
Director
Signature
/s/ Lara Meisner, Attorney-in-Fact
Issuer symbol
BCAX
Transactions as of
12 Sep 2024
Net transactions value
$0
Form type
4
Filing time
16 Sep 2024, 16:38:48 UTC
Previous filing
18 Jun 2024
Next filing
03 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCAX Stock Option (Right to Buy) Award $0 +23,746 $0.000000 23,746 12 Sep 2024 Common Stock 23,746 $18.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.